MPM Oncology Impact Management »

Ideaya Biosciences shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Ideaya Biosciences (IDYA) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Ideaya Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Ideaya Biosciences held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ideaya Biosciences by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-03-31 $7.0M 430k 16.38
2024-12-31 $11M 414k 25.70

More positions owned by MPM Oncology Impact Management

Madrigal Pharmaceuticals Common (MDGL)
Cullinan Therapeutics Common (CGEM)
Avidity Biosciences Common (RNA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
PTC Therapeutics Common (PTCT)
Zai Lab Adr (ZLAB)
Syndax Pharmaceuticals Common (SNDX)
Oric Pharmaceuticals Common (ORIC)
Tarsus Pharmaceuticals Common (TARS)
Xenon Pharmaceuticals Common (XENE)
Stoke Therapeutics Common (STOK)
Dyne Therapeutics Common (DYN)
Compass Therapeutics Common (CMPX)
Alkermes Common (ALKS)

View all positions for MPM Oncology Impact Management

Top funds holding Ideaya Biosciences

FMR
BlackRock
Capital Research Global Investors
Henderson Group
Vanguard Group
Federated Investors
Point72 Asset Management
Baker Bros. Advisors
State Street Corporation
Adage Capital Partners GP
Logos Global Management
Deerfield Management Company
Geode Capital Management
Fiera Capital Corporation
Morgan Stanley

View all funds holding Ideaya Biosciences